-
RBC Sees 'Multi-Year Growth Runway' for Edwards Lifesciences (EW); PT Raised
-
Edwards Lifesciences (EW) PT Lowered to $85 at RBC Capital
-
Edwards Lifesciences (EW) tumbles as guidance misses expectations
-
RBC Capital Starts Edwards Lifesciences (EW) at Outperform
-
Edwards Lifesciences (EW) PT Raised to $260 at RBC Capital
-
Edwards Lifesciences (EW) PT Raised to $250 at RBC Capital Into Q3
-
Edwards Lifesciences (EW) PT Raised to $217 at RBC Capital
-
Edwards Lifesciences (EW) PT Raised to $186 at RBC Capital
-
Edwards Lifesciences (EW) PT Raised to $182 at RBC Capital
-
Edwards Lifesciences (EW) PT Raised to $175 at RBC Capital
-
Edwards Lifesciences (EW) PT Raised to $153 at RBC Capital
-
Edwards Lifesciences (EW) PT Raised to $145 at RBC Capital; Reinforced Confidence Following Management Meetings
-
Notable Mergers and Acquisitions 11/28: (EW) (CDEV) (VRSK) (CTLT)
-
RBC Capital Upgrades Edwards Lifesciences (EW) to Outperform
-
Notable Analyst Rating Changes 04/24: (HAL) (COH) (CIT) Upgraded; (AAPL) (IRWD) (EW) Downgraded
-
RBC Capital Downgrades Edwards Lifesciences (EW) to Sector Perform
-
RBC Capital Downgrades Edwards Lifesciences (EW) to Outperform after Warning
-
RBC Capital Downgrades Edwards Lifesciences (EW) to Outperform
-
RBC Capital Upgrades Edwards Lifesciences (EW) to Top Pick, Price Target Offers 36% Upside
-
Daily State of the Markets 09/28: Second Thoughts?
-
RBC Capital Initiates Coverage on Several Medical Instruments & Supplies/Drug Stocks - Abbott Labs Named Top Pick

